264 related articles for article (PubMed ID: 20127552)
41. Medicinal Chemistry - XXIst International Symposium.
Chan D
IDrugs; 2010 Nov; 13(11):749-52. PubMed ID: 21046517
[TBL] [Abstract][Full Text] [Related]
42. Clinical Trials in CNS - SMi conference.
Filson S
IDrugs; 2007 Jan; 10(1):23-5. PubMed ID: 17187309
[No Abstract] [Full Text] [Related]
43. Delivery of therapeutic agents to the central nervous system: the problems and the possibilities.
Begley DJ
Pharmacol Ther; 2004 Oct; 104(1):29-45. PubMed ID: 15500907
[TBL] [Abstract][Full Text] [Related]
44. Applications of imaging biomarkers in the early clinical development of central nervous system therapeutic agents.
Cole PE; Schwarz AJ; Schmidt ME
Clin Pharmacol Ther; 2012 Feb; 91(2):315-20. PubMed ID: 22218072
[TBL] [Abstract][Full Text] [Related]
45. Challenges in the search for drugs to treat central nervous system disorders.
Enna SJ; Williams M
J Pharmacol Exp Ther; 2009 May; 329(2):404-11. PubMed ID: 19182069
[TBL] [Abstract][Full Text] [Related]
46. Advances and Progress in Drug Design - SMi's ninth annual meeting.
Welchman R
IDrugs; 2010 Apr; 13(4):239-42. PubMed ID: 20373252
[TBL] [Abstract][Full Text] [Related]
47. Gene-BIT Life Sciences' third annual world congress. Anti-neurodegenerative and anti-inflammation biotherapeutics.
Filep JG
IDrugs; 2010 Feb; 13(2):73-5. PubMed ID: 20127554
[TBL] [Abstract][Full Text] [Related]
48. Recent Developments in Wound Management: intelligent biomaterials to novel antimicrobials. 24 September 2009, London, UK.
Martin C
IDrugs; 2009 Nov; 12(11):695-8. PubMed ID: 19844855
[TBL] [Abstract][Full Text] [Related]
49. Novel therapeutic modalities to address nondrugable protein interaction targets.
De Souza EB; Cload ST; Pendergrast PS; Sah DW
Neuropsychopharmacology; 2009 Jan; 34(1):142-58. PubMed ID: 18754007
[TBL] [Abstract][Full Text] [Related]
50. Opportunities in systems biology to discover mechanisms and repurpose drugs for CNS diseases.
Mei H; Xia T; Feng G; Zhu J; Lin SM; Qiu Y
Drug Discov Today; 2012 Nov; 17(21-22):1208-16. PubMed ID: 22750722
[TBL] [Abstract][Full Text] [Related]
51. Can the immune system be harnessed to repair the CNS?
Popovich PG; Longbrake EE
Nat Rev Neurosci; 2008 Jun; 9(6):481-93. PubMed ID: 18490917
[TBL] [Abstract][Full Text] [Related]
52. Terrapinn's world influenza congress Europe 2009. Part 1.
Veryard C
IDrugs; 2010 Feb; 13(2):76-7. PubMed ID: 20127555
[TBL] [Abstract][Full Text] [Related]
53. European Respiratory Society (ERS) - 20th Annual Congress.
Seale JP
IDrugs; 2010 Nov; 13(11):762-4. PubMed ID: 21046521
[TBL] [Abstract][Full Text] [Related]
54. Drug Design--SMi's Third Annual Conference. 23-24 February 2004, London UK.
Austin S
IDrugs; 2004 Apr; 7(4):331-3. PubMed ID: 15057638
[No Abstract] [Full Text] [Related]
55. American Society for Clinical Pharmacology and Therapeutics (ASCPT)-111th annual meeting. 17-20 March 2010, Atlanta, GA, USA.
Veryard C
IDrugs; 2010 May; 13(5):286-8. PubMed ID: 20432179
[TBL] [Abstract][Full Text] [Related]
56. Adult neurogenesis pharmacology in neurological diseases and disorders.
Taupin P
Expert Rev Neurother; 2008 Feb; 8(2):311-20. PubMed ID: 18271715
[TBL] [Abstract][Full Text] [Related]
57. American Chemical Society-239th national meeting--Investigating new therapeutic candidates: part 1. 21-25 March 2010, San Francisco, CA, USA.
Macauley D
IDrugs; 2010 May; 13(5):289-91. PubMed ID: 20432180
[TBL] [Abstract][Full Text] [Related]
58. Generics, Supergenerics and Patent Strategies--SMi's 13th Annual Meeting.
Edwards C
IDrugs; 2010 Jul; 13(7):433-6. PubMed ID: 20582864
[TBL] [Abstract][Full Text] [Related]
59. Drug development for CNS disorders: strategies for balancing risk and reducing attrition.
Pangalos MN; Schechter LE; Hurko O
Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084
[TBL] [Abstract][Full Text] [Related]
60. Pain therapeutics--SMi's Ninth Annual Conference 8-9 June 2009, London, UK.
Kirkham K
IDrugs; 2009 Aug; 12(8):489-91. PubMed ID: 19629882
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
